Immunic Announces Acceptance Of Four Abstracts At MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that four abstracts highlighting new clinical, biomarker and
Share
Why It Matters
Immunic got accepted to show four research projects at a big medical meeting. This means doctors will learn about their medicine work and their science progress.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.